Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Cash Flow (2016 - 2025)

Ironwood Pharmaceuticals' Net Cash Flow history spans 16 years, with the latest figure at $74.7 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 22743.43% year-over-year to $74.7 million; the TTM value through Dec 2025 reached $127.2 million, up 3670.75%, while the annual FY2025 figure was $127.2 million, 3670.75% up from the prior year.
  • Net Cash Flow for Q4 2025 was $74.7 million at Ironwood Pharmaceuticals, up from $47.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $84.1 million in Q1 2023 and bottomed at -$565.5 million in Q2 2023.
  • The 5-year median for Net Cash Flow is $24.6 million (2024), against an average of -$7.4 million.
  • The largest annual shift saw Net Cash Flow crashed 535.3% in 2023 before it soared 22743.43% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $45.9 million in 2021, then surged by 78.87% to $82.0 million in 2022, then plummeted by 123.48% to -$19.3 million in 2023, then soared by 101.7% to $327000.0 in 2024, then skyrocketed by 22743.43% to $74.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Net Cash Flow are $74.7 million (Q4 2025), $47.6 million (Q3 2025), and -$15.0 million (Q2 2025).